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The promising clinical results obtained with engineered T cells, including chimeric antigen receptor (CAR)
therapy, call for further advancements to facilitate and broaden their applicability. One potentially beneficial
innovation is to exploit new T cell sources that reduce the need for autologous cell manufacturing and enable
cell transfer across histocompatibility barriers. Here we review emerging T cell engineering approaches that
utilize alternative T cell sources, which include virus-specific or T cell receptor-less allogeneic T cells,
expanded lymphoid progenitors, and induced pluripotent stem cell (iPSC)-derived T lymphocytes. The latter
offer the prospect for true off-the-shelf, genetically enhanced, histocompatible cell therapy products.T cells are essential mediators of immune defense against infec-
tious pathogens and cancer. Their insufficiency, which occurs in
hereditary or acquired immune deficiencies, results in life threat-
ening infections, increased cancer incidence, and disrupted
immunoregulation. T cells can also be harmful and cause normal
tissue destruction, as seen in autoimmune disorders, graft rejec-
tion, and graft-versus-host disease (GVHD). T cells develop from
precursors that rearrange germline antigen receptor VDJ genes
in the thymus, thereby generating clonotypic T cell receptors
(TCRs) that undergo positive and negative thymic selection
(Figure 1). The resulting T cells are self-restricted and tolerant
of self tissues. The newly generated T cell clones, known as
naive T cells, initially circulate throughout the body at low fre-
quency. Upon encountering antigen, T cells expand and acquire
effector and/or memory functions. This T cell priming requires
TCR engagement by Human Leucocyte Antigen (HLA)-peptide
complexes on the surface of antigen presenting cells (APCs)
and concomitant ligation of costimulatory receptors by ligands
borne by the APCs (Chen and Flies, 2013; Krogsgaard and
Davis, 2005).
Pathogen-specific T cells can be effectively expanded through
vaccination, a medical intervention that allows prevention of a
number of infectious diseases. In this instance, immunization
proceeds in vivo within secondary lymphoid organs where
T cells engage their TCRs on professional APCs that initiate pro-
ductive T cell activation and clonal expansion. Active immuniza-
tion has, however, proven far less effective when infection or
cancer is already established and progressing. In such circum-
stances, T cells, whether they are naturally activated or elicited
through immunization, often fail to eradicate disease owing to
their inadequate number or suboptimal function.
The infusion of T cells, or adoptive transfer, has proven to over-
come the limitations of active immunization in some pathologies.
The therapeutic use of isolated T cells began somewhat inadver-
tently with allogeneic bone marrow transplantation (BMT). The
use of whole marrow grafts containing donor T cells revealed
the beneficial (graft-versus-tumor responses) and deleterious
(GVHD) effects of adoptive T cell transfer (Ferrara and Deeg,
1991). Several forms of T cell therapy subsequently developed,including donor leukocyte infusion (Kolb et al., 2005) and virus-
specific T cell therapy (Riddell and Greenberg, 1995). These
therapies utilize ‘‘donor-derived T cells,’’ which tap into the
alloreactive potential of T cells harvested from a healthy donor
but expose the recipient to the risk of normal tissue destruction
by graft versus host (GVH) responses. In contrast, autologous
T cells, harvested from the intended recipient (Rosenberg
et al., 1986), are devoid of such toxic potential. However, autol-
ogous T cells with therapeutic potential may be lacking or
functionally impaired in patients with refractory infections or pro-
gressing cancer. Allogeneic and autologous T cells thus have
their respective advantages and disadvantages.
For some cancers, T cells may be isolated from surgically
removed tumors, which are enriched in tumor-reactive T cells
relative to peripheral blood. Tumor infiltrating lymphocytes
(TILs) can be isolated at quite a high frequency from melanoma
specimens, but this technique is not feasible or effective in
many other tumor types (Rosenberg et al., 2008; Wu et al.,
2012). Thus, we and others have sought to generate tumor-
targeted T cells through genetic engineering (Ho et al., 2003;
Sadelain et al., 2003). The rationale for T cell engineering is to
rapidly generate populations of T cells specific for any antigen
and, furthermore, to enhance their therapeutic (e.g., anti-tumor)
functions. Peripheral blood T cells are easily accessible and are a
perfectly suitable cell source for this purpose. Most current ther-
apies utilizing engineered T cells process autologous peripheral
blood T cells that are targeted to tumor antigens following retro-
viral transduction of a TCR or a chimeric antigen receptor (CAR).
In recent years, a few clinical trials have resulted in encouraging
and sometimes dramatic clinical responses (Couzin-Frankel,
2013). This Perspective article focuses on the sources of
T cells for adoptive cell therapy, starting from blood, hematopoi-
etic stem cell-derived lymphoid progenitor cells, embryonic
stem cell (ESC), or induced pluripotent stem cell (iPSC)-derived
T cells.
T Cell Engineering with TCRs and CARs
The general premise for engineering T cells for cancer immuno-
therapy is to rapidly generate tumor-targeted T cells, bypassingCell Stem Cell 16, April 2, 2015 ª2015 Elsevier Inc. 357
Figure 1. Human T Lymphocyte
Development
Hematopoietic stem cell-derived thymus-seeding
progenitors (TSPs) migrate into the thymus and
differentiate into an Early Thymic Progenitor (ETP)
upon rearrangement of the diversity (D) and joining
(J) regions of the TCR b locus. ETPs progress to a
pre-T cell state expressing CD1a and CD5. At this
stage, recombination of the variable (V) region of
the TCR b locus to form a complete rearranged
VDJ TCR b locus occurs almost simultaneously
with the rearrangement of the gene segments
encoding the gd TCR. Depending on the outcome
of the TCR segment rearrangements, the cells can
then follow an ab or a gd differentiation path. A
successful TCR b rearrangement leads to the
process of b-selection and emergence of a CD4+
immature single positive (ISP) T cell. The CD4 ISP
cell then develops into a double-positive (DP) cell
that expresses both CD4 and CD8 and has begun
to rearrange the V and J regions of the TCRa locus. The life span of DP thymocytes is limited as they quickly proceed to apoptosis if they do not receive a TCR-
mediated survival signal provided by the self-HLAmolecules of the thymic epithelium before maturing into CD4+CD8 and CD4CD8+ single-positive (SP) T cells.
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tive immune responses in vivo. Two categories of antigen recep-
tors are used to retarget T cell specificity: physiological TCRs
and synthetic receptors referred to as CARs (Figure 2). The
design of TCRs and CARs has steadily improved over the past
2 decades (Cohen et al., 2006, 2007; Robbins et al., 2008; Sade-
lain et al., 2003, 2009, 2013; Voss et al., 2008). TCRs are typically
cloned from patient tumor-reactive T cell clones (Johnson et al.,
2006), from humanized murine models (Cohen et al., 2005; Par-
khurst et al., 2009), or through the use of phage display technol-
ogy (Li et al., 2005; Varela-Rohena et al., 2008). In CARs, tumor
recognition is mediated by a single chain variable fragment
(scFv) derived from amonoclonal antibody or an antigen-binding
region isolated from an immunoglobulin (Ig) heavy and light chain
library. Unlike TCR-mediated antigen recognition, CARs function
independently of HLA and can therefore be used in any genetic
background. Second-generation CARs (Maher et al., 2002,
Figure 2) not only mediate antigen recognition and initiate
T cell activation but also harness costimulation to enhance
T cell function and prolong T cell persistence (Sadelain et al.,
2009). Over a decade ago, we selected the CD19 antigen as a
potential CAR target for B cell malignancies (Brentjens et al.,
2003) and made it the focus of our CAR therapy program.
Impressive results were obtained in patients with relapsed,
chemorefractory B cell malignancies. A number of patients
with chemorefractory B cell malignancies developed complete
responses after a single infusion of CAR T cells, as first reported
by theNational Cancer Institute for B cell lymphoma (Kochender-
fer et al., 2010, 2012), the University of Pennsylvania for chronic
lymphocytic leukemia (Kalos et al., 2011; Porter et al., 2011;
Brentjens et al., 2011), and Memorial Sloan Kettering Cancer
Center for acute lymphoblastic leukemia (ALL) (Brentjens et al.,
2013b; Davila et al., 2014a; Grupp et al., 2013; Lee et al., 2015;
Maude et al., 2014). These patients were treated with autologous
T lymphocytes that were retrovirally transduced with second-
generation, CD19-specific CARs (Davila et al., 2012). To date,
the most dramatic results have been obtained in adult and pedi-
atric patients with ALL (Brentjens et al., 2013b; Davila et al.,
2014a; Grupp et al., 2013; Lee et al., 2015; Maude et al., 2014).
Encouraging results have also been obtained in patients with358 Cell Stem Cell 16, April 2, 2015 ª2015 Elsevier Inc.CD19+ lymphomas, reviewed in Ramos et al. (2014) and Ko-
chenderfer and Rosenberg (2013). Third-generation CARs,
which contain two costimulatory domains along with an activa-
tion domain, may provide superior T cell function (Carpenito
et al., 2009; Pule et al., 2005; Till et al., 2012; Zhong et al.,
2010), although their effectiveness remains to be evaluated in
clinical trials.
Autologous T Cell Manufacture
The genetic modification of autologous peripheral blood T lym-
phocytes to generate tumor-targeted T cells is now awell-estab-
lished approach that was developed in a handful of academic
centers. The power and promise of TCR and CAR therapies
utilizing these manufacturing processes are best illustrated
by the exciting clinical results obtained with NY-ESO-1 TCR
(Robbins et al., 2011) and CD19 CAR T cells (Brentjens et al.,
2013b; Davila et al., 2014a; Grupp et al., 2013; Kochenderfer
et al., 2012, 2014).
These cell manufacturing processes combine T cell activation
and transduction steps to generate expanded, genetically tar-
geted T cell products. For example, T cells engineered to ex-
press specific CARs or TCRsmay be initiated from Ficoll-purified
PBMCs, which are next activated with anti-CD3 monoclonal
antibody (mAb) in the presence of irradiated allogeneic feeder
cells and transduced with a vector encoding either the CAR or
TCR a and b chains (Till et al., 2012; Morgan et al., 2006).
We and others have established cGMP-compliant large-scale
transduction and expansion processes, which are applicable
to CARs or TCRs, utilizing either g-retroviral or lentiviral T cell
manufacturing (Figure 3). These processes begin with the selec-
tion and activation of T cells from patient apheresis products us-
ing materials coated with anti-CD3 and anti-CD28 mAbs. In the
case of iron beads, CD3+CD28+ T cells are enriched using a
magnetic particle concentrator and subsequently cultured. Acti-
vated T cells are retrovirally transduced in RetroNectin-coated
cell bags and inoculated in a WAVE bioreactor where they are
expanded with a continuous perfusion regimen, reaching cell
densities of 10 million T cells/ml or more (Hollyman et al.,
2009). At the end of the production, the beads are removed
and the cells are formulated for immediate infusion or frozen
CD28CD80
HLA/
peptide
 
TCRα/β 
chains 
T cell
Tumor
 cellAPC
ζ
ζ
ε
δ
γ
ε
CD28
scFv
Ag
CD3ζ
CAR
TCR/CD3
 complex
Figure 2. Antigen Receptors Used for T Cell Engineering
Left: Structure of the ab heterodimeric T cell receptor (TCR) associated with the multi-chain CD3 complex (g, d, ε, and z) and flanked by CD28, a costimulatory
receptor constitutively expressed in most ab-T cells. Right: Structure of a prototypical second-generation chimeric antigen receptor (CAR), comprising an scFv
for antigen recognition, the CD3z cytoplasmic domain for T cell activation, and the CD28 cytoplasmic domain to enhance T cell function and persistence (Maher
et al., 2002).
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depending on the disease and the targeted T cell dose. This
semi-closed large-scale manufacturing platform can be easily
adapted for various vectors and for the expansion of either pa-
tient (autologous) or donor (allogeneic) T cells. It successfully
supports several ongoing clinical trials in which therapeutic effi-
cacy has been demonstrated (Brentjens et al., 2011, 2013a;
Davila et al., 2014b). This process starts from bulk T cells har-
vested from each individual subject. Several groups are currently
evaluatingwhat T cell phenotype and T cell subset or subsets ac-
count for the anti-tumor activity of these cells and what will be
optimal tools to activate and expand T cells for different T cell
therapies. Various means to enhance the activation and expan-
sion of T cells for adoptive cell therapy have been reviewed else-
where (Vacchelli et al., 2013).
The functional, proliferative, andpersistence potential of adop-
tively transferred T lymphocytes is determined by multiple fac-
tors. These include the TCR or CAR design, the manufacturing
platform, the selected T cell subsets, and the differentiation stage
of the harvested T cells. Peripheral blood T cells comprise naive
(TN), stem cell memory (TSCM), central memory (TCM), effector
memory (TEM), and terminal effector (TE) cells (Klebanoff et al.,
2012). Several groups have investigated which of these T cell
subsets are best suited for use in different adoptive therapy set-
tings (Klebanoff et al., 2012; Riddell et al., 2014). In non-human
primates and murine NSG models, T cell transfer studies have
shown that virus-specific and CAR-redirected anti-tumor CD8
TEM rapidly mature to terminal effector T cells and do not persist
beyond 7–14 days, while a subset of transferred CD8+ TE/CM can
acquire memory cell features and persist for months and even
years (Wang et al., 2012). Polyclonal CD8+ TCM isolation from leu-
kopheresis products, followed by CD3/CD28 activation without
exogenous feeder cells and cell expansion in IL-2/IL-15, has
thus been developed on a clinical scale and is currently in use
for the generation of autologous CAR-redirected CD19-specific
CD8+ TE/CM for adoptive transfer after autologous hematopoietic
stem cell transplantation (HSCT) for high-risk CD19+ non-Hodg-
kin lymphomas (Wang et al., 2012). Additional variations on themanufacturing schemas exemplified here have been reported
or are under development (DiGiusto and Cooper, 2007; Laport
et al., 2003; Savoldo et al., 2011; Somerville et al., 2012; Wang
and Rivie`re, 2015).
It remains to be determined how the cell attributes imparted by
in vivo persistence of antigen-specific T cells correlate with those
conferring increased anti-tumor efficacy (Biasco et al., 2015;
Flynn and Gorry, 2014; Xu et al., 2014). Defining optimal, potent
T cell products of specified composition for adoptive cell therapy
will require careful phenotypic and biological characterization,
taking in account manufacturing and economic practicalities
(Heathman et al., 2015).
Allogeneic T Cells as a Substrate for T Cell Engineering
The promising clinical results of engineered T cell therapy could
be further amplified and broadened if potent and histocompati-
ble T cells were readily available. Autologous approaches have
a proven track record, but personalized manufacture may be
challenging in some instances, for example in patients with
chemotherapy or HIV-induced immune deficiency or in small in-
fants.While T cells can be easily harvested fromdonors, their use
is compromised by the high alloreactive potential. Owing to their
ontogeny, TCRs are naturally prone to react against non-autolo-
gous tissues, recognizing either allogeneic HLA molecules or
other polymorphic gene products, referred to as minor antigens
(Afzali et al., 2007). This propensity underlies the high risk of graft
rejection in transplant recipients and of GVHD in recipients of
donor-derived T cells. Thus, bulk, unselected donor T cells are
prone to cause normal tissue destruction and may be lethal on
occasion. To provide an acceptable risk-benefit ratio, allogeneic
T cells must be devoid of alloreactive potential. Two strategies
designed to overcome the risk of GVH reactions have been pro-
posed, based on the selection of virus-specific TCRs devoid of
GVH reactivity or the ablation of TCR expression.
Virus-Specific T Cells
Donor-derived virus-specific T cells can be administered to
virus-infected, HLA-matched recipients with a reduced risk of
GVHD. For this purpose, donor T cells from a seropositive donorCell Stem Cell 16, April 2, 2015 ª2015 Elsevier Inc. 359
Figure 3. General Schema of Autologous T Cell Manufacturing
The semi-closed system relies on the use of a cell washer to wash the apheresis product before freezing and after thawing, the capture of CD3+CD28+ T cells with
magnetic beads or microbeads. For magnetic beads subsequent selection is performed on the ClinExVivo magnetic particle concentrator (MPC). Thereafter, T
cells are transduced with a viral vector expressing a TCR or a CAR, expanded in a bioreactor (e.g., Wave Bioreactor), debeaded on the ClinExVivo MPC, and
formulated. Adapted from Hollyman et al. (2009).
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antigens. The APCs may consist of syngeneic Epstein-Barr virus
(EBV)-transformed B cells (Heslop et al., 1994), peptide pulsed
dendritic cells, or artificial APCs (Latouche and Sadelain, 2000;
Papanicolaou et al., 2003). Repeated stimulation with viral anti-
gen gradually increases viral specificity and concomitantly de-
pletes alloreactivity. Although alloreactivity and unanticipated
TCR cross-reactivity cannot be prospectively eliminated with
full certainty (Cameron et al., 2013; Morgan et al., 2013), virus-
specific T cell lines generated in this manner have shown
dramatic responses in EBV, cytomegalovirus (CMV) and adeno-
virus-infected recipients without causing severe GVHD (Heslop
et al., 1996; Papadopoulos et al., 1994). Recent studies have
suggested that virus-specific T cells can be administered to mul-
tiple recipients with limited risk of GVHD (Doubrovina et al., 2012;
Haque et al., 2007). Virus-specific T cells may thus serve as
cellular vehicles for TCR or CAR therapy. A first trial testing
this approach showed that T cells expanded in vivo in response
to viral reactivation although anti-tumor activity was modest
(Cruz et al., 2013). While the relatively limited expansion poten-
tial of virus-specific T cells and the sometimes unpredictable
cross-reactivity of TCR-mediated antigen recognition are valid
concerns, this approach to treat viral infections represents a first
step toward multi-recipient T cell product manufacturing (Wang
and Rivie`re, 2015).
TRC-less Allogeneic Peripheral Blood T Cells
If the endogenous TCR cannot be tamed, one may abrogate
its expression, making the engineered TCR or CAR the sole
driver of T cell activation and clonal expansion. With the advent
of gene disruption technologies, this approach is now within360 Cell Stem Cell 16, April 2, 2015 ª2015 Elsevier Inc.reach. Four technologies based on the use of targeted nucle-
ases, including meganucleases, zinc-finger nucleases (ZFNs),
transcription activator-like effector nucleases (TALEN), and
CRISPR/Cas9, enable gene disruption in human cells (Kim and
Kim, 2014; Sander and Joung, 2014). ZFNs and CRISPR/Cas9
are presently the most developed of these tools and have been
shown to efficiently target the HIV co-receptor CCR5 (Holt
et al., 2010; Mandal et al., 2014; Tebas et al., 2014). The ablation
of endogenous TCR expression has been achieved using tar-
geted ZFNs or TALENs that disrupt the constant regions of
TCRA and TCRB genes (Berdien et al., 2014; Provasi et al.,
2012; Torikai et al., 2012). Unlike unedited, allogeneic T cells,
TCR-deleted lymphocytes retargeted by CAR or TCR gene
transfer do not mediate GVH reactivity. Their long-term persis-
tence could potentially be compromised, since homeostatic pro-
liferation is partially dependent on TCR-major histocompatibility
complex (MHC) interactions. However, T lymphocytes that have
acquired a central memory phenotype are less dependent on the
TCR for homeostatic proliferation (Surh and Sprent, 2008) and
proliferate in response to cytokines (Provasi et al., 2012). Their
long-term persistence, relative to that of unedited T lympho-
cytes, has not yet been fully characterized. Furthermore, gene
disruption technologies are still in early stages of development
and require optimization to afford high frequency bi-allelic
gene targeting without causing off-target mutations, which could
potentially alter T cell function or predispose to cell transforma-
tion. Prevention of GVHD would require that virtually all T cells
bear a disrupted TCR gene, requiring high-efficiency targeting
and robust purging of unmodified cells to ensure T cell safety.
Similar to the virus-specific T cell paradigm, it is unknown to
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including antigen-specific restimulation, TCR or CAR transduc-
tion, gene editing, and cell selection, will yield sufficiently large
batches of functional T cells that meet the needs for multiple
recipient infusions. Thus, allogeneic T cell approaches are still la-
bor intensive and constrained by the limited replicative potential
of mature T cells (Gattinoni et al., 2012).
Interestingly, allogeneic T cells may not cause GVHD in some
particular circumstances. Thus, patients infused with T cells
collected after allogeneic transplantation have not developed
any GVHD-like syndrome (Davila et al., 2014a; Lee et al., 2015;
Maude et al., 2014). More strikingly, CD19 CAR-targeted donor
T cells show reduced GVHD potential in allogeneic recipient
mice (reported at the American Society of Hematology annual
meeting in 2012) and in human patients infused with CD19
CAR-modified donor leukocytes (Kochenderfer et al., 2013). A
mechanistic explanation for these intriguing observations is still
lacking.
Lymphoid Progenitor Therapy
While T cells can cause GVHD, their precursors do not, as they
undergo positive and negative selection in the recipient’s
thymus. Taking advantage of this requires the ability to expand
T cell precursors in culture, which is now possible due to ad-
vances in understanding T cell development (Awong et al.,
2007; Rothenberg, 2011; Shah and Zu´n˜iga-Pflu¨cker, 2014).
T cell precursors lack the ability to initiate GVH reactions
because they complete their differentiation in the recipient’s
thymus wherein they become restricted to host MHC and yield
T lymphocytes that are host tolerant (Zakrzewski et al., 2006).
When transduced with a CAR, allogeneic lymphoid progenitors
yield tumor-targeted T cells without causing GVHD (Zakrzewski
et al., 2008). The main advantage of using T cell precursors for
immunotherapy is that this approach does not require strict his-
tocompatibility between donors and recipients. In mice, this
therapy works with unrelated fully mismatched cells just as
well as with autologous cells. T cell precursor immunotherapy
may therefore allow for a true ‘‘off-the-shelf’’ therapy, if lymphoid
progenitor cell manufacturing can be scaled up.
Pluripotent Stem Cells as a Source of Therapeutic
T Lymphocytes
The development of cellular therapeutics relying on functionally
validated, banked, broadly histocompatible cell types would
have a major impact on the applicability and cost of adoptive
T cell therapies. This prospect raises the challenge of artificially
generating ideal T cells rather than modifying those naturally
formed. Pluripotent stem cells can give rise to a variety of so-
matic cells (Inoue et al., 2014; Murry and Keller, 2008; Takahashi
et al., 2007) and thus have in principle the potential to serve as an
endless supply of therapeutic T lymphocytes. A few reports sup-
port the feasibility of generating T lymphocytes from human
ESCs and iPSCs in vitro (Kennedy et al., 2012; Nishimura et al.,
2013; Themeli et al., 2013; Timmermans et al., 2009; Vizcardo
et al., 2013).
Antigen Specificity
The first requirement for therapeutic function is specific antigen
recognition, which is physiologically mediated by the TCR. ESCs
and most iPSCs bear TCR a and b loci in the germline configura-tion. These undergo random rearrangements during lymphoid
differentiation, thus generating polyclonal T cells of undeter-
mined specificity and HLA restriction. This unpredictable reper-
toire severely limits the usefulness and potential for expansion
and functional characterization of T cells derived from ESCs/
iPSCs. Two approaches to dictate the specificity of iPSC-
derived T cells have been hitherto reported. One utilizes iPSCs
that bear rearranged TCR genes, providing a known antigen
specificity (Nishimura et al., 2013; Vizcardo et al., 2013; Wakao
et al., 2013). Re-differentiation of iPSCs derived from mucosal-
associated invariant T (MAIT) cells expressing the invariant
T cell receptor Va7.2 or established viral- and tumor-specific
T cell clones gives rise to T lymphocytes bearing the same
TCR as the parental T cell from which the iPSC clone was estab-
lished, although re-rearrangement of a remaining germline TCR a
locus may result in multiple TCRs. This approach to afford anti-
gen-specificity for cancer immunotherapy requires laborious
cloning of antigen-specific T cells and the availability of the
desired antigen-specific T cells for every prospective recipient.
Another approach is to genetically transfer a receptor for
antigen of known specificity. We previously demonstrated that
T cell-derived iPSCs (TiPSCs) expressing a CAR (CAR-TiPSC)
provide an effective means to concomitantly exploit the unlim-
ited proliferative potential of iPSCs and direct the antigen spec-
ificity of iPSC-derived T cells (Themeli et al., 2013). In contrast to
TCR transfer, CAR engineering yields T cells with unrestricted
antigen recognition and enhanced potency owing to the costi-
mulatory signals provided through the CAR.
Determining T Lineage Commitment and T Cell Fate
The functional properties of T lymphocytes depend not only on
their differentiation stage and engineered features, as discussed
above, but also on their lineage subtype (gd or ab T cells, effector
or regulatory subsets) (Vantourout and Hayday, 2013). It is there-
fore essential to generate T cells of the desired functional subset.
Natural human T lymphoid development is outlined in Figure 1.
Lymphopoietic progenitors seem to follow these steps overall
throughout ESC/iPSC in vitro differentiation. TiPSCs generated
from an ab-TCR-bearing T cell indeed give rise to ab-TCR+ cells.
However, their phenotype, whether pre or post antigen-expan-
sion, may not be that of a typical ab-T cell. Expanded TiPSC-
derived T cells are CD3+CD7+CD5loTCRab+CD56+ and either
double negative for CD4 and CD8 or CD8a+CD8b– (Nishimura
et al., 2013; Themeli et al., 2013). Antigen-activated and
expanded CAR-TiPSC-T cells display an effector memory
phenotype (CD45RA+CD27–CD28–CCR7–) (Themeli et al.,
2013). Microarray gene expression analyses and detailed immu-
nophenotypic profiling provided some clarification for these
unexpected findings, establishing that the in vitro generated
CAR-TiPSC-T cells possess an innate gd T cell-like profile,
even though they express their endogenous ab-TCR (Themeli
et al., 2013). Significantly, their in vivo anti-tumor function was
comparable to natural, peripheral blood-derived gd T cells
collected from the same donor and transduced with the same
CAR (Themeli et al., 2013). Furthermore, Nishimura et al. (2013)
observed the emergence of a few central memory TiPSC-
derived T cells (CCR7+CD27+CD28+), although these cells had
very low CCR7 and CD28 expression. In aggregate, these find-
ings indicate that although the TiPSC-T cells express their
rearranged endogenous ab-TCR on their surface, they acquireCell Stem Cell 16, April 2, 2015 ª2015 Elsevier Inc. 361
Figure 4. Perspectives for Synthetic TiPSC-Derived T Cell Generation
TiPSCs can be generated from one donor and utilized for the production of synthetic T lymphocytes engineered to possess optimized properties such as (1)
antigen specificity through a CAR or TCR, (2) enhanced function (e.g., introducing costimulatory molecules), (3) elimination of alloreactivity and partial broadening
of applicability (e.g., strategies to knock out the TCR expression without perturbing the T lymphoid differentiation process), and (4) broad histocompatibility by
selection or genetic modification of the HLA loci.
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to that of natural naive or memory CD8ab+ T lymphocytes.
One study showed efficient generation of CD4+CD8a+TCR+
cells, which almost exclusively differentiated into CD8aa+ cells
upon stimulation with antigen (Vizcardo et al., 2013). Other
studies showed absent or minor generation of double positive
CD4+CD8a+ cells, but no detection of CD8b has yet been re-
ported. A better understanding of the requirements for inducing
CD4+CD8ab+ cells will pave the way for the generation of
CD8ab+ and CD4+ T cells, including effector and regulatory
T cells.
Interestingly, both CAR-TiPSC-T cells and regenerated MAIT
cells (Wakao et al., 2013) express CD56 and CD161, suggesting
that the innate nature of the TiPSC-T cells is independent of the
identity of the initially reprogrammed T cell subtype. It is note-
worthy that lineage diversion has been previously observed in
transgenic TCRab mice (Baldwin et al., 2005; Egawa et al.,
2008; Terrence et al., 2000), wherein T cells distinct from wild-
type natural killer (NK), NK-T, or CD4 or CD8 single-positive
T cells displayed gd T cell features, including expression of
CD8a and low levels of CD5 (Terrence et al., 2000). Furthermore,
in vitro differentiated T cells derived from TCR-engineered hu-
man CD34+ hematopoietic progenitors display an NK cell-like
phenotype (Zhao et al., 2007). These observations suggest that
the presence of rearranged TCR genes influences T cell fate,
similar to reports in TCR transgenic mice (Baldwin et al., 2005).
Accordingly, mature CD4+CD8+ and single-positive T cells
developed from TCR-engineered CD34+ hematopoietic progen-
itors when the TCR cDNAs were introduced in the pre-T cell
stage of differentiation (Snauwaert et al., 2014), consistent with
time-dependent TCR expression causing lineage diversion.
Alternatively, considering that some features of TiPSC-derived
T cells, such as their CD8a+CD8b phenotype, expression of
CD161 and low expression of CD5, are also found in innate-362 Cell Stem Cell 16, April 2, 2015 ª2015 Elsevier Inc.like T cells generated in fetal development (Cupedo et al.,
2009; Spits and Cupedo, 2012), it may be that their innate char-
acter is imparted by a fetal-like hematopoietic stem cell interme-
diate committed to innate lymphopoiesis (Kennedy et al., 2012;
Mold et al., 2010; Yuan et al., 2012) and intrinsically skewed
toward embryonic characteristics (Murry and Keller, 2008).
Further investigation of the mechanisms underlying in vitro T
lymphoid differentiation of TiPSCs is needed to better direct
T cell subset differentiation and further shape the functional attri-
butes of induced T cells.
T Cell Functionality
Beyond antigen specificity, two critical features that will deter-
mine the therapeutic relevance of pluripotent cell-derived
T cells are their potential for in vivo persistence and sustained
functionality. Few studies have comprehensively assessed the
functional profile of ESC or iPSC-derived T cells in vitro or
upon adoptive transfer in vivo. As previously mentioned, the
random TCR rearrangements occurring in ESC/iPSC-derived
T cells limit the feasibility of studying antigen-specific expansion
and function. Therefore, ESC/iPSC-derived T cell function has
been assessed only in in vitro assays showing IFNg secretion af-
ter unspecific stimulation (Timmermans et al., 2009). Expanded
tumor- and viral-specific TiPSC-derived T cells (100- to 1,000-
fold) secrete IFN-g after unspecific stimulation and lyse target
cells in an antigen-specific manner in vitro (Nishimura et al.,
2013). Re-differentiated MAIT cells were shown to successfully
function in vivo against mycobacterium infection, although in a
non-antigen-specific manner (Wakao et al., 2013). CAR-TiPSC
T cells generated in culture expanded robustly upon CD19
engagement by the CAR (up to 1,000-fold over 3 weeks) and
showed anti-tumor efficacy against a CD19+ lymphoma in a
xenogeneic murine model, comparable to their natural counter-
parts harvested from peripheral blood (from the same donor) and
transduced with the same CAR (Themeli et al., 2013). The latter
Cell Stem Cell
Perspectivestudy provided the proof of principle that human iPSC-derived T
lymphocytes generated in vitro possessed anti-tumor function
in vivo. Further studies are needed to investigate the in vitro
expansion potential and the in vivo capabilities of iPSC-derived
T lymphocytes.
Striking a Balance between Preventing Anti-Host
Reactivity and Escaping Immune Rejection Is Key
Whereas anti-host reactivity may cause unacceptable toxicity,
immune rejection of non-autologous T cells will curtail their effi-
cacy. Therefore, escaping immune rejection, ensuring sufficient
persistence and possibly long term engraftment, are further crit-
ical requirements to enable off-the-shelf adoptive T cell therapy.
One immediate approach to solve this problem is to bank cells
with common HLA haplotypes, as proposed for EBV-reactive
T cells (Gallot et al., 2014; Leen et al., 2013) or iPSC/ESCs (Gour-
raud et al., 2012; Nakatsuji et al., 2008; Stacey et al., 2013;
Turner et al., 2013). Although this approach is certainly a valuable
first step toward broader applicability of adoptive T cell therapy,
it is still constrained by HLA matching and by donor availability.
Furthermore, the establishment of iPSC/ESC banks requires the
generation of multiple iPSC lines from multiple donors, com-
pounded by the eventual need to identify T cells of an appro-
priate specificity and HLA restriction, followed by extensive
safety studies and validation of the individual clones. The alter-
native is to genetically target HLA genes to generate histocom-
patible cell products (Riolobos et al., 2013; Torikai et al., 2012).
Targeting multiple HLA loci in primary T lymphocytes may be
feasible but poses technical challenges owing to the substantial
safety validation required for each cell product. HLA engineering
and biosafety testing may be easier to perform in pluripotent
stem cells (Riolobos et al., 2013). In contrast to primary T cell ma-
nipulations, the genetic engineering of iPSCs results in fully
modified clonal lines, which can be extensively evaluated (Papa-
petrou et al., 2011). However, disruption of HLA loci would
expose cells to NK cell-mediated rejection. Further cell engineer-
ing including overexpression of HLA-E or HLA-G has been pro-
posed as a solution to confer NK resistance (Riolobos et al.,
2013; Torikai et al., 2012).
Perspectives for ‘‘Synthetic T Cells’’
Stem cell reprogramming not only offers potential access to an
unlimited source of therapeutic T lymphocytes, but it also pro-
vides an excellent platform for performing additional engineering
intended to enhance the therapeutic value of induced T cells. The
genetic engineering of TiPSCs with CARs is the first example of
an efficient strategy to concomitantly harness the unlimited
availability of iPSCs and direct the specificity and functional po-
tential of iPSC-derived T cells (Themeli et al., 2013). The use of
iPSCs further opens up new perspectives for the generation of
histocompatible, off-the-shelf T cells that could eventually be
administered to multiple recipients. The combination of iPSC
technology and immune engineeringmay thus provide an oppor-
tunity to generate T cells that uniquely combine favorable
attributes including antigen specificity, lack of alloreactivity,
enhanced functional properties and histocompatibility (Figure 4).
Several challenges remain, including the ability to control T line-
age specification (to ab- or gd-T cells, NK-T, CD8, CD4, or reg-
ulatory T cells), differentiation to an optimal maturation stage(e.g., naive or stem central memory T cells) (Gattinoni et al.,
2012), and acquisition of an optimal functional and proliferative
potential (Sadelain et al., 2003). Natural, autologous T cells
represent the best-defined cell source for adoptive cell therapy
today, and they are the cornerstone of present cell-based cancer
immunotherapy. Induced, engineered T cells derived from allo-
geneic pluripotent stem cell sources may play an important
role in the future.ACKNOWLEDGMENTS
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